Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma.
Immunomodulation
Immunotherapy
Macrophages
Tumor Biomarkers
Tumor Microenvironment
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
accepted:
07
02
2023
entrez:
23
2
2023
pubmed:
24
2
2023
medline:
3
3
2023
Statut:
ppublish
Résumé
Epithelial ovarian cancer (EOC) is among the top five causes of cancer-related death in women, largely reflecting early, prediagnosis dissemination of malignant cells to the peritoneum. Despite improvements in medical therapies, particularly with the implementation of novel drugs targeting homologous recombination deficiency, the survival rates of patients with EOC remain low. Unlike other neoplasms, EOC remains relatively insensitive to immune checkpoint inhibitors, which is correlated with a tumor microenvironment (TME) characterized by poor infiltration by immune cells and active immunosuppression dominated by immune components with tumor-promoting properties, especially tumor-associated macrophages (TAMs). In recent years, TAMs have attracted interest as potential therapeutic targets by seeking to reverse the immunosuppression in the TME and enhance the clinical efficacy of immunotherapy. Here, we review the key biological features of TAMs that affect tumor progression and their relevance as potential targets for treating EOC. We especially focus on the therapies that might modulate the recruitment, polarization, survival, and functional properties of TAMs in the TME of EOC that can be harnessed to develop superior combinatorial regimens with immunotherapy for the clinical care of patients with EOC.
Identifiants
pubmed: 36822672
pii: jitc-2022-005968
doi: 10.1136/jitc-2022-005968
pmc: PMC9950980
pii:
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: RS is minority shareholder of Sotio Biotech a.s. JF and IT are employees of Sotio Biotech.
Références
Clin Cancer Res. 2018 Apr 1;24(7):1536-1545
pubmed: 29217526
Clin Cancer Res. 2019 Jul 1;25(13):3759-3771
pubmed: 30760478
Springerplus. 2016 Jul 28;5(1):1197
pubmed: 27516935
Oncotarget. 2017 Jun 13;8(24):39021-39032
pubmed: 28380460
Blood. 2001 Feb 1;97(3):785-91
pubmed: 11157498
Cell Rep. 2021 Oct 19;37(3):109844
pubmed: 34686340
Gynecol Oncol. 2017 Oct;147(1):181-187
pubmed: 28698008
PLoS One. 2013 Dec 06;8(12):e79769
pubmed: 24324582
Ther Adv Med Oncol. 2020 Jul 24;12:1758835920944116
pubmed: 32782491
Cancer Sci. 2018 May;109(5):1309-1318
pubmed: 29527764
Genome Biol. 2016 May 23;17(1):108
pubmed: 27215396
Int J Mol Sci. 2016 Mar 01;17(3):320
pubmed: 26938527
Ann Oncol. 2019 Jul 1;30(7):1080-1087
pubmed: 31046082
Clin Cancer Res. 2005 Aug 15;11(16):6030-9
pubmed: 16115948
Int J Mol Sci. 2019 May 15;20(10):
pubmed: 31096567
Oncogene. 2015 Mar 5;34(10):1241-52
pubmed: 24662827
Science. 2011 Mar 25;331(6024):1612-6
pubmed: 21436454
Int Rev Cell Mol Biol. 2020;354:107-164
pubmed: 32475471
J Hematol Oncol. 2019 Sep 14;12(1):98
pubmed: 31521196
Am J Pathol. 2002 Feb;160(2):537-48
pubmed: 11839574
Annu Rev Pathol. 2020 Jan 24;15:123-147
pubmed: 31530089
Cell Death Dis. 2020 Apr 20;11(4):249
pubmed: 32312959
Pathol Int. 2009 May;59(5):300-5
pubmed: 19432671
Cancers (Basel). 2021 Dec 11;13(24):
pubmed: 34944851
J Immunother Cancer. 2021 Jan;9(1):
pubmed: 33452206
Clin Cancer Res. 2017 Jul 15;23(14):3711-3720
pubmed: 28167507
Cell. 2010 Apr 2;141(1):39-51
pubmed: 20371344
Immunity. 2003 Jun;18(6):849-61
pubmed: 12818165
BMC Genomics. 2017 Mar 21;18(1):243
pubmed: 28327095
Cancer Cell. 2019 Mar 18;35(3):473-488.e6
pubmed: 30889381
Cancer Sci. 2014 Aug;105(8):966-73
pubmed: 24826982
Cancer Immunol Res. 2018 Dec;6(12):1578-1592
pubmed: 30396909
BMC Pharmacol Toxicol. 2020 Sep 11;21(1):67
pubmed: 32912307
Front Oncol. 2021 Jul 26;11:704001
pubmed: 34381726
Cells. 2021 Apr 20;10(4):
pubmed: 33924237
Oncoimmunology. 2013 Jan 1;2(1):e23033
pubmed: 23483678
Cancer Res. 2007 Jun 1;67(11):5064-6
pubmed: 17545580
Eur Rev Med Pharmacol Sci. 2017 Jun;21(11):2596-2603
pubmed: 28678326
Cell. 2021 Feb 4;184(3):792-809.e23
pubmed: 33545035
Tumour Biol. 2016 Apr;37(4):5031-7
pubmed: 26541760
Oncotarget. 2016 Nov 15;7(46):75339-75352
pubmed: 27659538
Int J Cancer. 2009 Jul 15;125(2):367-73
pubmed: 19378341
JAMA Oncol. 2019 Oct 01;5(10):1411-1420
pubmed: 31343665
Oncotarget. 2016 May 10;7(19):28697-710
pubmed: 26885690
Sci Transl Med. 2022 Mar 16;14(636):eabg8402
pubmed: 35294258
Cancer Sci. 2010 Oct;101(10):2128-36
pubmed: 20860602
J Immunol. 2012 Jun 15;188(12):6389-98
pubmed: 22586039
F1000Prime Rep. 2014 Mar 03;6:13
pubmed: 24669294
J Exp Med. 2001 Apr 2;193(7):839-46
pubmed: 11283156
Nat Commun. 2019 Jul 5;10(1):3000
pubmed: 31278254
Clin Cancer Res. 2018 Jun 15;24(12):2749-2757
pubmed: 29559563
Int Immunopharmacol. 2020 Jul;84:106471
pubmed: 32305830
Mol Cancer. 2016 Sep 09;15(1):58
pubmed: 27613122
Cancer Res. 2007 Sep 15;67(18):8900-5
pubmed: 17875732
Proc Natl Acad Sci U S A. 2020 Jan 7;117(1):541-551
pubmed: 31889004
Cancer Immunol Res. 2019 Nov;7(11):1864-1875
pubmed: 31462409
Front Oncol. 2014 Jun 06;4:137
pubmed: 24936477
Nature. 2016 Nov 17;539(7629):443-447
pubmed: 27828943
Cancer Immunol Immunother. 2010 Dec;59(12):1877-1884
pubmed: 20820775
Nature. 2014 Sep 25;513(7519):559-63
pubmed: 25043024
Cancers (Basel). 2020 May 29;12(6):
pubmed: 32486098
Front Immunol. 2020 Feb 05;11:120
pubmed: 32117271
Cancer Biol Ther. 2014 Aug;15(8):1061-7
pubmed: 24841852
Clin Cancer Res. 2022 Aug 15;28(16):3590-3602
pubmed: 35675036
NPJ Precis Oncol. 2021 Dec 17;5(1):101
pubmed: 34921236
Commun Biol. 2020 Sep 22;3(1):524
pubmed: 32963283
J Immunother Cancer. 2017 Jul 18;5(1):53
pubmed: 28716061
Signal Transduct Target Ther. 2021 Mar 26;6(1):127
pubmed: 33767177
J Clin Oncol. 2017 Jul 1;35(19):2193-2202
pubmed: 28471727
Nat Rev Drug Discov. 2020 Oct;19(10):711-736
pubmed: 32884152
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Gynecol Oncol. 2013 Oct;131(1):169-73
pubmed: 23863356
Nat Rev Cancer. 2015 Nov;15(11):668-79
pubmed: 26493647
Aging (Albany NY). 2021 Oct 11;13(19):23210-23232
pubmed: 34633990
J Clin Invest. 1995 May;95(5):2391-6
pubmed: 7738202
Front Immunol. 2022 Oct 21;13:1031746
pubmed: 36341460
Cold Spring Harb Perspect Biol. 2014 Jun 02;6(6):
pubmed: 24890514
Cancer Res. 2010 Aug 1;70(15):6171-80
pubmed: 20631075
Cancer Cell. 2013 Feb 11;23(2):249-62
pubmed: 23410977
Oncol Rep. 2017 Jun;37(6):3189-3200
pubmed: 28440503
J Immunol. 2005 Jul 15;175(2):1197-205
pubmed: 16002723
Nat Biomed Eng. 2020 May;4(5):489-498
pubmed: 32203281
Cancer Res. 2014 Jan 1;74(1):24-30
pubmed: 24220244
Am J Pathol. 2002 Oct;161(4):1215-21
pubmed: 12368195
Semin Immunol. 2009 Oct;21(5):257-64
pubmed: 19540774
Clin Cancer Res. 2003 Nov 15;9(15):5721-8
pubmed: 14654557
Gynecol Oncol. 2017 Sep;146(3):484-490
pubmed: 28698009
J Clin Invest. 2016 Nov 1;126(11):4157-4173
pubmed: 27721235
Nature. 2019 Aug;572(7769):392-396
pubmed: 31367043
J Immunother Cancer. 2018 Jun 20;6(1):61
pubmed: 29921320
Cancer Res. 2021 Nov 15;81(22):5706-5719
pubmed: 34561272
BMB Rep. 2019 Jun;52(6):360-372
pubmed: 31186085
Cancer Lett. 2019 Apr 1;446:38-48
pubmed: 30660652
Ann Oncol. 2019 Aug 1;30(8):1381-1392
pubmed: 31114846
Clin Cancer Res. 2020 Aug 15;26(16):4268-4279
pubmed: 32398324
Curr Oncol. 2021 Oct 19;28(5):4234-4246
pubmed: 34677277
Front Oncol. 2020 Jan 24;9:1512
pubmed: 32039007
Invest New Drugs. 2021 Oct;39(5):1284-1297
pubmed: 33852104
Gynecol Oncol. 2017 Mar;144(3):607-612
pubmed: 28065619
Chin J Cancer Res. 2014 Oct;26(5):622-6
pubmed: 25400429
Nat Biotechnol. 2020 Aug;38(8):947-953
pubmed: 32361713
Lancet Oncol. 2021 May;22(5):620-631
pubmed: 33743851
Cell Metab. 2019 Jun 4;29(6):1376-1389.e4
pubmed: 30930171
Nature. 2016 Nov 17;539(7629):437-442
pubmed: 27642729
Clin Exp Immunol. 2022 Jul 22;209(1):4-21
pubmed: 35020853
PLoS One. 2012;7(6):e38541
pubmed: 22685580
JCI Insight. 2020 Sep 17;5(18):
pubmed: 32780724
Br J Cancer. 2017 Oct 24;117(9):1371-1382
pubmed: 28898232
Sci Rep. 2020 Apr 8;10(1):6096
pubmed: 32269279
Oncotarget. 2017 Aug 7;8(42):72147-72156
pubmed: 29069775
J Ovarian Res. 2014 Feb 08;7:19
pubmed: 24507759
Front Cell Dev Biol. 2020 Sep 09;8:564601
pubmed: 33015058
J Breast Cancer. 2019 Jan 02;22(1):38-51
pubmed: 30941232
Cell Rep. 2015 Apr 28;11(4):577-91
pubmed: 25892230
Nat Commun. 2020 Mar 19;11(1):1459
pubmed: 32193378
Oncotarget. 2015 May 30;6(15):13416-33
pubmed: 25968567
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33115946
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33097612
Cancer Res. 2015 Nov 15;75(22):4742-52
pubmed: 26471360
JAMA Oncol. 2019 Mar 1;5(3):393-401
pubmed: 30676622
N Engl J Med. 2011 Dec 29;365(26):2484-96
pubmed: 22204725
Mol Oncol. 2014 Oct;8(7):1231-9
pubmed: 24816187
Nat Med. 2004 Sep;10(9):942-9
pubmed: 15322536
Cell Signal. 2020 Apr;68:109539
pubmed: 31935430
Cancer Res. 2018 Jul 1;78(13):3560-3573
pubmed: 29739756
Oncotarget. 2017 Aug 24;8(57):96496-96505
pubmed: 29228548
Blood. 2007 Dec 15;110(13):4319-30
pubmed: 17848619
Cancer Chemother Pharmacol. 2013 Apr;71(4):1041-50
pubmed: 23385782
Target Oncol. 2015 Mar;10(1):111-23
pubmed: 24928772
Int Rev Cell Mol Biol. 2021;364:111-137
pubmed: 34507781
Br J Cancer. 2018 Jan;118(1):9-16
pubmed: 29319049
Asian Pac J Cancer Prev. 2013;14(10):5883-90
pubmed: 24289594
Trends Immunol. 2002 Nov;23(11):549-55
pubmed: 12401408
JAMA Oncol. 2019 Dec 1;5(12):1731-1738
pubmed: 31600397
Cancer Immunol Res. 2018 Oct;6(10):1260-1273
pubmed: 30012633
Ann N Y Acad Sci. 2022 Jun;1512(1):154-173
pubmed: 35247207
Cell Rep. 2017 Aug 15;20(7):1654-1666
pubmed: 28813676
Vaccines (Basel). 2015 Sep 10;3(3):703-29
pubmed: 26378585
BMC Cancer. 2011 May 30;11:210
pubmed: 21619709
J Transl Med. 2006 Jul 06;4:30
pubmed: 16824216
Immunity. 2014 Jul 17;41(1):14-20
pubmed: 25035950
Cold Spring Harb Perspect Biol. 2013 Jan 01;5(1):a008748
pubmed: 23284042
Oncol Lett. 2017 Jan;13(1):159-166
pubmed: 28123537
Front Oncol. 2018 Oct 04;8:423
pubmed: 30338242
J Immunother Cancer. 2020 Aug;8(2):
pubmed: 32819974
J Clin Oncol. 2019 Apr 20;37(12):946-953
pubmed: 30811285
Nature. 2011 Jun 08;475(7355):222-5
pubmed: 21654748
Clin Cancer Res. 2017 Oct 1;23(19):5846-5857
pubmed: 28536305
Nat Genet. 2021 Sep;53(9):1334-1347
pubmed: 34493872
Gynecol Oncol. 2016 Nov;143(2):393-397
pubmed: 27569584
Ann Oncol. 2017 May 01;28(5):996-1004
pubmed: 28453702
Lancet Oncol. 2020 Sep;21(9):1155-1164
pubmed: 32771088
Cancers (Basel). 2022 Oct 25;14(21):
pubmed: 36358644
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5
pubmed: 17360651
Cell. 2003 Mar 7;112(5):645-57
pubmed: 12628185
Gene Ther. 2010 Mar;17(3):360-9
pubmed: 20033066
Front Oncol. 2017 Feb 22;7:24
pubmed: 28275576
Front Oncol. 2020 Feb 27;10:221
pubmed: 32175278
Clin Cancer Res. 2021 Oct 15;27(20):5536-5545
pubmed: 34326131
J Int Med Res. 2021 Dec;49(12):3000605211066245
pubmed: 34939862
Lancet Oncol. 2019 Jun;20(6):862-876
pubmed: 31076365
Sci Transl Med. 2017 May 10;9(389):
pubmed: 28490665
Int J Oncol. 2012 Sep;41(3):1094-100
pubmed: 22751940
Mol Med Rep. 2012 Sep;6(3):645-50
pubmed: 22751779
Sci Transl Med. 2020 Jul 15;12(552):
pubmed: 32669424
J Immunol Res. 2021 May 22;2021:9912188
pubmed: 34124272
Immunol Rev. 2019 Jul;290(1):6-23
pubmed: 31355494
Front Immunol. 2022 Oct 27;13:1045957
pubmed: 36389711
Cancer Res. 2011 Sep 1;71(17):5697-706
pubmed: 21742772
J Clin Oncol. 2018 Nov 10;36(32):3223-3230
pubmed: 30265610
Cell. 2020 Aug 20;182(4):886-900.e17
pubmed: 32783918
Lancet Oncol. 2021 Jul;22(7):1034-1046
pubmed: 34143970
Mol Cancer. 2016 Feb 12;15:13
pubmed: 26868378
Nat Commun. 2021 Feb 9;12(1):877
pubmed: 33563975
Front Immunol. 2018 May 04;9:847
pubmed: 29780381
Cancers (Basel). 2018 Sep 29;10(10):
pubmed: 30274280
Front Cell Dev Biol. 2020 Aug 11;8:758
pubmed: 32850861
Mol Cell Proteomics. 2018 Feb;17(2):270-289
pubmed: 29141914
Am J Pathol. 2010 Sep;177(3):1053-64
pubmed: 20651229
Cancer Res. 2004 Aug 15;64(16):5839-49
pubmed: 15313928
Sci Transl Med. 2016 Mar 2;8(328):328rv4
pubmed: 26936508
Int J Cancer. 2014 Jan 1;134(1):32-42
pubmed: 23784932
Front Oncol. 2021 Dec 20;11:788365
pubmed: 34988021
Bioconjug Chem. 2021 Aug 18;32(8):1581-1592
pubmed: 34289694
Cancer Cell. 2014 Jun 16;25(6):846-59
pubmed: 24898549
Trends Cancer. 2022 May;8(5):426-444
pubmed: 35181272
Nat Rev Clin Oncol. 2022 Jun;19(6):402-421
pubmed: 35354979
Cancer Immunol Res. 2022 Jan;10(1):40-55
pubmed: 34795032
Clin Cancer Res. 1997 Jun;3(6):999-1007
pubmed: 9815777
J Immunother Cancer. 2021 Oct;9(10):
pubmed: 34645669
N Engl J Med. 2019 Dec 19;381(25):2391-2402
pubmed: 31562799
Gynecol Oncol. 2019 Aug;154(2):314-322
pubmed: 31204078
Cancer Res. 2007 Jun 15;67(12):5708-16
pubmed: 17575137
Nat Med. 2003 Oct;9(10):1269-74
pubmed: 14502282
Immunity. 2018 Dec 18;49(6):1148-1161.e7
pubmed: 30552023
Immunol Cell Biol. 2019 Mar;97(3):258-267
pubmed: 30746824